Research programme: pain therapeutics - Ensysce Biosciences

Drug Profile

Research programme: pain therapeutics - Ensysce Biosciences

Alternative Names: PF-14

Latest Information Update: 24 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PharmacoFore
  • Developer Ensysce Biosciences
  • Class Opioid analgesics
  • Mechanism of Action Opioid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Inflammatory pain

Most Recent Events

  • 24 Feb 2016 Discontinued for Inflammatory pain in USA (unspecified route)
  • 19 Jan 2016 Signature Therapeutics has merged into Ensysce Biosciences
  • 03 Sep 2012 PharmacoFore is now called Signature Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top